PMD-026

N/A

Report date: 2026/05/23 20:00:57
NME

Base Information

Drug NamePMD-026
Drug Alias NamePMD-026
ClassificationSmall molecules
Mechanisms of ActionRibosomal protein S6 kinase inhibitors
TargetsRibosomal protein S6 kinase
Therapy Area/IndicationsMetastatic breast cancerPrimary MyelofibrosisTriple Negative Breast Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesPhoenix Molecular Designs
China Registration ClassN/A

Develop Information

Active CompaniesWashington University School Of MedicinePhoenix Molecular Designs
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerPrimary MyelofibrosisTriple Negative Breast Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A